Who are GF-001001-00's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Combined therapy LDV and SOF, Daclatasvir plus Asunaprevir, Zepatier plus Sofosbuvir, Viekira Pak ± ribavirin, Daclinza and Sunvepra, Ledipasvir and sofosbuvir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gf-001001-00.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

GF-001001-00 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GF-001001-00 (GF-001001-00) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NS5A inhibitor. Area: Infectious Diseases.

phase 2 NS5A inhibitor HCV NS5A Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

GF-001001-00 (GF-001001-00) — Ferrer Internacional S.A.. GF-001001-00 is a small molecule that targets the HCV NS5A protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GF-001001-00 TARGET	GF-001001-00	Ferrer Internacional S.A.	phase 2	NS5A inhibitor	HCV NS5A
Combined therapy LDV and SOF	Combined therapy LDV and SOF	Yassin Abdelghaffar Charity Center for Liver Disease and Research	marketed	Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor)	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Daclatasvir plus Asunaprevir	Daclatasvir plus Asunaprevir	Myeong Jun Song	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease
Zepatier plus Sofosbuvir	Zepatier plus Sofosbuvir	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B RNA polymerase
Viekira Pak ± ribavirin	Viekira Pak ± ribavirin	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein, HCV NS3/4A serine protease
Daclinza and Sunvepra	Daclinza and Sunvepra	Pusan National University Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Ledipasvir and sofosbuvir	Ledipasvir and sofosbuvir	National Taiwan University Hospital	marketed	Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor)	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NS5A inhibitor class)

Bristol-Myers Squibb · 2 drugs in this class
AbbVie · 1 drug in this class
Ferrer Internacional S.A. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GF-001001-00 — Competitive Intelligence Brief. https://druglandscape.com/ci/gf-001001-00. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing